PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-1… (NCT00526916) | Clinical Trial Compass
CompletedPhase 1
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
United States18 participantsStarted 2007-09-04
Plain-language summary
The purpose of this protocol is to measure peripheral benzodiazepine receptors in the brain using positron emission tomography (PET) and compare the imaging results between patients and healthy people.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
* INCLUSION CRITERIA:
Common to patients with neurocysticercosis and healthy subjects:
Ages between 18 and 75, inclusive.
Patients must meet the inclusion criteria of protocol 85-I-0127.
CONTROL SUBJECTS:
Are healthy based on history, physical exams, ECG, and lab tests.
EXCLUSION CRITERIA:
COMMON TO ALL SUBJECTS:
Current psychiatric illness, substance abuse or severe systemic disease based on history and physical exam.
ECG with clinically significant abnormalities. Any existing physical exam and ECG within one year will be reviewed and if none already exists in the chart, these will be obtained and reviewed.
Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual guideline of RSC.
Pregnancy or breast feeding.
Claustrophobia.
Positive HIV test.
Cannot lie on back for a few hours for the PET scans.
Presence of ferromagnetic metal in the body or heart pacemaker.
ADDITIONAL EXCLUSION CRITERIA FOR PATIENTS:
Medically unstable.
Seizures are not well controlled with medications.
A history of brain disease other than neurocysticercosis.
Laboratory tests with clinically significant abnormalities unrelated to neurocysticercosis or its treatment.
ADDITIONAL EXCLUSION CRITERIA FOR HEALTHY SUBJECTS:
Laboratory tests with clinically significant abnormalities.
A history of brain disease.
The usage of nonsteroidal and other anti-inflammatory medications is not an exclusion criterion.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Binding of [C-11]PBR28 at peripheral benzodiazepine receptors